1.
Oncology
; 45(5): 350-3, 1988.
Artigo
em Inglês
| MEDLINE
| ID: mdl-3045726
RESUMO
In a randomized trial, 105 postmenopausal women with advanced carcinoma of the breast received tamoxifen or aminoglutethimide or combined tamoxifen and aminoglutethimide. No differences were found in the rate of responses and duration of responses between the treatment groups. Toxicity was significantly greater (p less than 0.01) in patients who received aminoglutethimide.